journal article·2022-03Open access

Ionizable lipid-assisted efficient hepatic delivery of gene editing elements for oncotherapy

Chunhui Li, Tongren Yang, Yuhua Weng, Mengjie Zhang, Deyao Zhao, Shuai Guo, Bo Hu, Wanxuan Shao, Xiaoxia Wang, Abid Hussain, Xing-Jie Liang, Yuanyu Huang

Abstract

CRISPR/Cas9-based gene editing has emerged as a powerful biotechnological tool, that relies on Cas9 protein and single guided RNA (sgRNA) to edit target DNA. However, the lack of safe and efficient delivery carrier is one of the crucial factors restricting its clinical transformation. Here, we report an ionizable lipid nanoparticle (iLP181, pKa = 6.43) based on iLY1809 lipid enabling robust gene editing in vitro and in vivo. The iLP181 effectively encapsulate psgPLK1, the best-performing plasmid expressing for both Cas9 protein and sgRNA targeting Polo-like kinase 1 (PLK1). The iLP181/psgPLK1 nanoformulation showed uniformity in size, regular nanostructure and nearly neutral zeta potential at pH 7.4. The nanoformulation effectively triggered editing of PLK1 gene with more than 30% efficiency in HepG2-Luc cells. iLP181/psgPLK1 significantly accumulated in the tumor for more than 5 days after a single intravenous injection. In addition, it also achieved excellent tumor growth suppression compared to other nucleic acid modalities such as siRNA, without inducing adverse effects to the main organs including the liver and kidneys. This study not only provides a clinically-applicable lipid nanocarrier for delivering CRISPR/Cas system (even other bioactive molecules), but also constitutes a potential cancer treatment regimen base on DNA editing of oncogenes.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · CRISPR and Genetic Engineering · Virus-based gene therapy research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (50)

Show source-provided references
1. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy10.1126/sciadv.abc9450 ↗
2. COL7A1 editing via CRISPR/Cas9 in recessive dystrophic epidermolysis bullosa10.1016/j.ymthe.2017.07.005 ↗
3. Reversal of phenotypic abnormalities by CRISPR/Cas9-Mediated gene correction in Huntington disease patient-derived induced pluripotent stem cells10.1016/j.stemcr.2017.01.022 ↗
4. Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing10.1186/s13045-017-0489-9 ↗
5. Negative feedback regulation of HIV-1 by gene editing strategy10.1038/srep31527 ↗
6. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis10.1016/j.cell.2015.02.038 ↗
7. CRISPR-Cas13a mediated nanosystem for attomolar detection of canine parvovirus type 210.1016/j.cclet.2019.10.032 ↗
8. An enhanced method for nucleic acid detection with CRISPR-Cas12a using phosphorothioate modified primers and optimized gold-nanopaticle strip
9. Clinical advances of siRNA therapeutics10.1002/jgm.3097 ↗
10. Therapeutic siRNA: state of the art10.1038/s41392-020-0207-x ↗
11. RNAi therapeutic and its innovative biotechnological evolution10.1016/j.biotechadv.2019.04.012 ↗
12. Update on clinical gene therapy for hemophilia10.1182/blood-2018-07-820720 ↗
13. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector10.1038/73464 ↗
14. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN10.1089/hum.2018.015 ↗
15. Virus used in gene therapies may pose cancer risk, dog study hints
16. Efficient hepatic delivery and protein expression enabled by optimized mRNA and ionizable lipid nanoparticle
17. siRNA knockdown of RRM2 effectively suppressed pancreatic tumor growth alone or synergistically with doxorubicin10.1016/j.omtn.2018.08.003 ↗
18. Targeted delivery of chlorogenic acid by mannosylated liposomes to effectively promote the polarization of TAMs for the treatment of glioblastoma
19. Core-shell lipid-polymer nanoparticles as a promising ocular drug delivery system to treat glaucoma10.1016/j.cclet.2019.04.048 ↗
20. Co-delivery of gemcitabine and Mcl-1 SiRNA via cationic liposome-based system enhances the efficacy of chemotherapy in pancreatic cancer10.1166/jbn.2019.2762 ↗
21. Co-delivery of paclitaxel and PLK1-targeted siRNA using aptamer-functionalized cationic liposome for synergistic anti-breast cancer effects in vivo10.1166/jbn.2019.2751 ↗
22. Safety and immunogenicity of two RNA-based covid-19 vaccine candidates10.1056/NEJMoa2027906 ↗
23. An mRNA vaccine against SARS-CoV-2 - preliminary report10.1056/NEJMoa2022483 ↗
24. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing10.1038/s41565-020-0669-6 ↗
25. A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing10.1016/j.celrep.2018.02.014 ↗
26. Fast and efficient CRISPR/Cas9 genome editing in vivo enabled by bioreducible lipid and Messenger RNA nanoparticles10.1002/adma.201902575 ↗
27. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo10.1038/nbt.3471 ↗
28. Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles10.1073/pnas.1520244113 ↗
29. Rational design of cationic lipids for siRNA delivery10.1038/nbt.1602 ↗
30. Zhang · 2016 · 1
31. Targeting polo-like kinase 1 for cancer therapy10.1038/nrc1841 ↗
32. Thermo-triggered release of CRISPR-cas9 system by lipid-encapsulated gold nanoparticles for tumor therapy10.1002/anie.201708689 ↗
33. Plk1 inhibitors in cancer therapy: from laboratory to clinics10.1158/1535-7163.MCT-15-0897 ↗
34. The microgravity enhanced polymer-mediated siRNA gene silence by improving cellular uptake10.1007/s41048-020-00121-y ↗
35. A photo-triggerable aptamer nanoswitch for spatiotemporal controllable siRNA delivery10.1039/D0NR00301H ↗
36. Elaboration on the distribution of hydrophobic segments in the chains of amphiphilic cationic polymers for small interfering RNA delivery10.1021/acsami.7b07337 ↗
37. Targeted delivery of CRISPR/Cas9-Mediated cancer gene therapy via liposome-templated hydrogel nanoparticles10.1002/adfm.201703036 ↗
38. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo10.1002/anie.201203263 ↗
39. Lipid-like materials for low-dose, in vivo gene silencing10.1073/pnas.0910603106 ↗
40. Deciphering the impact of PEG antifouling layer on surface attached functional peptides in regulating cell behaviors10.1016/j.cclet.2019.10.038 ↗
41. On the role of helper lipids in lipid nanoparticle formulations of siRNA10.1039/C9NR09347H ↗
42. Lipid nanoparticle formulations for enhanced Co-delivery of siRNA and mRNA10.1021/acs.nanolett.8b01101 ↗
43. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity10.1038/ncomms5277 ↗
44. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms10.1038/mt.2010.85 ↗
45. Overcoming cellular barriers for RNA therapeutics10.1038/nbt.3802 ↗
46. Core role of hydrophobic Core of polymeric nanomicelle in endosomal escape of siRNA10.1021/acs.nanolett.0c04468 ↗
47. Knocking down disease: a progress report on siRNA therapeutics10.1038/nrg3978 ↗
48. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape10.1038/nbt.2612 ↗
49. pH-tunable endosomolytic oligomers for enhanced nucleic acid delivery10.1002/adfm.200601188 ↗
50. An open-label, Multicenter, phase I, dose escalation study with phase II expansion cohort to determine the safety, pharmacokinetics, and preliminary antitumor activity of intravenous TKM-080301 in subjects with advanced hepatocellular carcinoma10.1634/theoncologist.2018-0838 ↗